Aperio Group LLC raised its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 19.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,980 shares of the biotechnology company’s stock after purchasing an additional 3,900 shares during the quarter. Aperio Group LLC’s holdings in Ligand Pharmaceuticals were worth $3,284,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Ligand Pharmaceuticals by 48.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,101 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 359 shares in the last quarter. Harbor Advisors LLC acquired a new stake in Ligand Pharmaceuticals during the third quarter valued at approximately $204,000. Round Table Services LLC acquired a new stake in Ligand Pharmaceuticals during the third quarter valued at approximately $205,000. Ameritas Investment Partners Inc. boosted its holdings in Ligand Pharmaceuticals by 9.4% during the second quarter. Ameritas Investment Partners Inc. now owns 1,799 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 154 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Ligand Pharmaceuticals during the third quarter valued at approximately $230,000.
In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $145.00, for a total transaction of $362,500.00. Following the transaction, the director now owns 33,149 shares of the company’s stock, valued at approximately $4,806,605. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Stephen L. Sabba sold 925 shares of the company’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $137.25, for a total value of $126,956.25. Following the transaction, the director now directly owns 26,985 shares in the company, valued at approximately $3,703,691.25. The disclosure for this sale can be found here. Insiders sold a total of 63,024 shares of company stock worth $9,934,043 over the last three months. 8.30% of the stock is owned by company insiders.
Ligand Pharmaceuticals Inc. (NASDAQ LGND) opened at $157.14 on Friday. The company has a market capitalization of $3,317.36, a P/E ratio of 227.74, a PEG ratio of 1.68 and a beta of 1.07. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05. Ligand Pharmaceuticals Inc. has a 1-year low of $95.08 and a 1-year high of $170.30.
LGND has been the topic of several recent analyst reports. HC Wainwright set a $169.00 target price on Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Craig Hallum reissued a “buy” rating and issued a $170.00 target price (up from $160.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, November 15th. Finally, Roth Capital set a $158.00 target price on Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Ligand Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $150.83.
COPYRIGHT VIOLATION WARNING: “Aperio Group LLC Buys 3,900 Shares of Ligand Pharmaceuticals Inc. (LGND)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/18/aperio-group-llc-buys-3900-shares-of-ligand-pharmaceuticals-inc-lgnd.html.
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.